Ctxr stock forecast 2025 technical indicators point to a

Technical indicators point to a potential golden cross for CTXR by mid-Q1 2025, reinforcing the bullish "ctxr stock forecast 2025" scenario. RSI levels remain neutral, suggesting room for upward momentum without entering overbought territory yet. More bearish on Nordstrom (JWN) , Argus double downgraded the stock to Sell from Buy. Okunewitch goes on to outline the potential of Lymphir as a revenue generator, adding of the drug candidate, “One of the key considerations for assessing the value of Lymphir is to look at the commercial opportunity within cutaneous T-cell lymphoma (CTCL). There are an estimated 30k-40k patients in the US living with CTCL and ~3k new cases per year. When Ontak was originally on the market in the early 2000s, it generated sales in the range of $30M-$40M per year. However, the market has changed significantly in the years since, and we believe these changes to the treatment landscape have increased the potential market opportunity for Lymphir – management estimates the opportunity as high as $400M.” Portfolio managers evaluating small-cap biotech find the "ctxr stock forecast 2025" compelling, especially under scenarios of sector consolidation. If M&A activity picks up, CTXR’s valuation could see a premium above its base projections.